Qiagen N.V. (NYSE:QGEN) Receives Average Recommendation of "Hold" from Brokerages

Key Points

• Qiagen N.V. has received a consensus rating of "Hold" from eleven research firms, with eight analysts giving a hold recommendation and three analysts recommending a buy.
• The average 12-month price target for Qiagen's stock is approximately $49.69, with various firms adjusting their price targets following recent reports.
• Qiagen reported $0.60 earnings per share for the last quarter, meeting the consensus estimate, with revenue of $533.54 million, exceeding expectations.

Qiagen N.V. (NYSE:QGEN - Get Free Report) has been given a consensus rating of "Hold" by the eleven research firms that are presently covering the stock, MarketBeat.com reports. Eight equities research analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $49.6865.

Several research firms recently weighed in on QGEN. Cowen reiterated a "hold" rating on shares of Qiagen in a report on Thursday, August 7th. Bank of America lifted their price target on shares of Qiagen from $50.00 to $53.00 and gave the company a "buy" rating in a report on Thursday, June 26th. Wall Street Zen cut shares of Qiagen from a "strong-buy" rating to a "buy" rating in a report on Monday, August 11th. Barclays initiated coverage on shares of Qiagen in a report on Tuesday, June 24th. They set an "overweight" rating and a $55.00 target price on the stock. Finally, UBS Group boosted their target price on shares of Qiagen from $48.00 to $50.00 and gave the company a "neutral" rating in a report on Thursday, August 7th.

Qiagen Stock Up 0.2%

Shares of NYSE QGEN opened at $45.39 on Tuesday. The company has a quick ratio of 1.35, a current ratio of 1.61 and a debt-to-equity ratio of 0.25. Qiagen has a 52 week low of $37.63 and a 52 week high of $51.88. The firm's fifty day moving average is $48.42 and its 200 day moving average is $44.72. The company has a market cap of $10.09 billion, a price-to-earnings ratio of 26.82, a PEG ratio of 2.39 and a beta of 0.64.

Qiagen (NYSE:QGEN - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported $0.60 earnings per share for the quarter, meeting the consensus estimate of $0.60. The business had revenue of $533.54 million for the quarter, compared to analysts' expectations of $523.97 million. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. The firm's revenue for the quarter was up 7.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.55 earnings per share. Qiagen has set its Q3 2025 guidance at 0.580- EPS. FY 2025 guidance at 2.350-2.350 EPS. On average, equities research analysts expect that Qiagen will post 2.26 earnings per share for the current year.

Institutional Trading of Qiagen

A number of hedge funds have recently modified their holdings of QGEN. Ameriprise Financial Inc. boosted its holdings in shares of Qiagen by 66.3% during the 4th quarter. Ameriprise Financial Inc. now owns 63,026 shares of the company's stock valued at $2,807,000 after buying an additional 25,134 shares in the last quarter. Cetera Investment Advisers raised its position in shares of Qiagen by 14.4% in the 4th quarter. Cetera Investment Advisers now owns 11,297 shares of the company's stock worth $505,000 after purchasing an additional 1,418 shares during the last quarter. OMERS ADMINISTRATION Corp raised its position in shares of Qiagen by 37.8% in the 4th quarter. OMERS ADMINISTRATION Corp now owns 12,400 shares of the company's stock worth $552,000 after purchasing an additional 3,400 shares during the last quarter. Point72 Asset Management L.P. raised its position in shares of Qiagen by 170.6% in the 4th quarter. Point72 Asset Management L.P. now owns 125,646 shares of the company's stock worth $5,595,000 after purchasing an additional 79,207 shares during the last quarter. Finally, Teza Capital Management LLC raised its position in shares of Qiagen by 30.4% in the 4th quarter. Teza Capital Management LLC now owns 28,991 shares of the company's stock worth $1,291,000 after purchasing an additional 6,766 shares during the last quarter. Institutional investors own 70.00% of the company's stock.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.